1
|
Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv 2024; 8:817-826. [PMID: 37782770 PMCID: PMC10874903 DOI: 10.1182/bloodadvances.2023009801] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 09/24/2023] [Accepted: 09/27/2023] [Indexed: 10/04/2023] Open
Abstract
ABSTRACT More than 130 drugs have been suspected to induce immune hemolytic anemia. Comparative studies measuring the risk of drug-induced immune hemolytic anemia (DIIHA) are lacking. We aimed (1) to detect new signals of DIIHA, excluding vaccines, and (2) to assess the association between all suspected drugs and the occurrence of immune hemolytic anemia in a nationwide comparative study. The new signals were identified using a disproportionality study (case/noncase design) in the World Pharmacovigilance Database, Vigibase, among the cases of adverse drug reactions reported up to February 2020 (>20 million). We then conducted a comparative study in the French National health database that links sociodemographic, out-of-hospital, and hospital data for the entire population (67 million individuals). Associations between exposure to drugs (those already reported as DIIHA, plus new signals identified in Vigibase) and incident cases of immune hemolytic anemia (D59.0 and D59.1 diagnosis codes of the International Classification of Diseases, version 10) from 2012 to 2018 were assessed with case-control and case-crossover designs. In Vigibase, 3371 cases of DIIHA were recorded. Fifty-nine new signals were identified resulting in a final list of 112 drugs marketed in France and measurable in the nationwide cohort (n = 4746 patients with incident immune hemolytic anemia included in the case-control analysis matched with 22 447 controls from the general population). We identified an association between immune hemolytic anemia occurrence and some antibiotics, antifungal drugs, ibuprofen, acetaminophen, furosemide, azathioprine, and iomeprol.
Collapse
Affiliation(s)
- Julien Maquet
- Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
- Clinical Investigation Center 1436, Team PEPSS Pharmacologie en Population, Toulouse University Hospital, Toulouse, France
| | - Margaux Lafaurie
- Clinical Investigation Center 1436, Team PEPSS Pharmacologie en Population, Toulouse University Hospital, Toulouse, France
- Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France
| | - Marc Michel
- Department of Internal Medicine, National Reference Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hopitaux de Paris, University Paris-Est Créteil, Créteil, France
| | - Maryse Lapeyre-Mestre
- Clinical Investigation Center 1436, Team PEPSS Pharmacologie en Population, Toulouse University Hospital, Toulouse, France
- Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France
| | - Guillaume Moulis
- Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
- Clinical Investigation Center 1436, Team PEPSS Pharmacologie en Population, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
2
|
Gaucher L, Sabatier P, Katsahian S, Jannot AS. Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures. J Clin Epidemiol 2023; 162:127-134. [PMID: 37657615 DOI: 10.1016/j.jclinepi.2023.08.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 05/29/2023] [Accepted: 08/21/2023] [Indexed: 09/03/2023]
Abstract
OBJECTIVES The purpose of this study was to systematically review the statistical methods used in pharmacovigilance studies without a priori hypotheses. STUDY DESIGN AND SETTING A systematic review was performed on studies published in the MEDLINE database between 2012 and 2021. The included studies were analyzed for database name and type, statistical methods, anatomical therapeutic chemical class for the studied drug(s), and SOC MedDRA classification for the studied adverse drug reaction. RESULTS Ninety-two studies were included, with pharmacovigilance databases being the most used type. Disproportionality analysis using frequentist or Bayesian methods was the most common statistical method employed. The most studied drug classes were anti-infectives, nervous system drugs, and antineoplastics and immunomodulators. However, no common procedure was implemented to correct for multiple testing. CONCLUSION This review highlights the limited number of statistical methods employed for pharmacovigilance studies without a priori hypotheses, with no established consensus-based method and a lack of interest in multiple testing correction. The establishment of guidelines is recommended to improve the performance of such studies.
Collapse
Affiliation(s)
- Louis Gaucher
- HeKA INSERM, INRIA Paris, Centre de Recherche des Cordeliers Paris, Université Paris Cité, Paris, France.
| | - Pierre Sabatier
- Clinical Research Unit, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - Sandrine Katsahian
- HeKA INSERM, INRIA Paris, Centre de Recherche des Cordeliers Paris, Université Paris Cité, Paris, France; Clinical Research Unit, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - Anne-Sophie Jannot
- HeKA INSERM, INRIA Paris, Centre de Recherche des Cordeliers Paris, Université Paris Cité, Paris, France; Banque Nationale de Données Maladies Rares, Direction des Services Numériques, APHP, Paris, France
| |
Collapse
|
3
|
Linard M, Bezin J, Hucteau E, Joly P, Garrigue I, Dartigues JF, Pariente A, Helmer C. Antiherpetic drugs: a potential way to prevent Alzheimer's disease? Alzheimers Res Ther 2022; 14:3. [PMID: 34996520 PMCID: PMC8742322 DOI: 10.1186/s13195-021-00950-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Accepted: 12/15/2021] [Indexed: 12/23/2022]
Abstract
Background Considering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) which may represent a new means of prevention, well tolerated and easily accessible. Subsequently, several epidemiological studies have shown a reduction in the risk of dementia in subjects treated with AHDs, but the biological plausibility of this association and the impact of potential methodological biases need to be discussed in more depth. Methods Using a French medico-administrative database, we assessed the association between the intake of systemic AHDs and the incidence of (i) dementia, (ii) Alzheimer’s disease (AD), and (iii) vascular dementia in 68,291 subjects over 65 who were followed between 2009 and 2017. Regarding potential methodological biases, Cox models were adjusted for numerous potential confounding factors (including proxies of sociodemographic status, comorbidities, and use of healthcare) and sensitivity analyses were performed in an attempt to limit the risk of indication and reverse causality biases. Results 9.7% of subjects (n=6642) had at least one intake of systemic AHD, and 8883 incident cases of dementia were identified. Intake of at least one systemic AHD during follow-up was significantly associated with a decreased risk of AD (aHR 0.85 95% confidence interval [0.75–0.96], p=0.009) and, to a lesser extent with respect to p values, to both dementia from any cause and vascular dementia. The association with AD remained significant in sensitivity analyses. The number of subjects with a regular intake was low and prevented us from studying its association with dementia. Conclusions Taking at least one systemic AHD during follow-up was significantly associated with a 15% reduced risk of developing AD, even after taking into account several potential methodological biases. Nevertheless, the low frequency of subjects with a regular intake questions the biological plausibility of this association and highlights the limits of epidemiological data to evaluate a potential protective effect of a regular treatment by systemic AHDs on the incidence of dementia Supplementary Information The online version contains supplementary material available at 10.1186/s13195-021-00950-0.
Collapse
Affiliation(s)
- Morgane Linard
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.
| | - Julien Bezin
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.,Pharmacology Department, Bordeaux University Hospital, F-33076, Bordeaux, France
| | - Emilie Hucteau
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France
| | - Pierre Joly
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France
| | - Isabelle Garrigue
- Virology Department, Bordeaux University Hospital and University of Bordeaux, CNRS-UMR 5234, F-33000, Bordeaux, France
| | - Jean-François Dartigues
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.,Memory Consultation, CMRR, Bordeaux University Hospital, F-33076, Bordeaux, France
| | - Antoine Pariente
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.,Pharmacology Department, Bordeaux University Hospital, F-33076, Bordeaux, France
| | - Catherine Helmer
- University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France
| |
Collapse
|
4
|
Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz-Perroteau C. Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS). Pharmacoepidemiol Drug Saf 2020; 30:320-333. [PMID: 33099844 DOI: 10.1002/pds.5161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 11/10/2022]
Abstract
PURPOSES Drug induced acute liver injury (ALI) is a frequent cause of liver failure. Case-based designs were empirically assessed and calibrated in the French National claims database (SNDS), aiming to identify the optimum design for drug safety alert generation associated with ALI. METHODS All cases of ALI were extracted from SNDS (2009-2014) using specific and sensitive definitions. Positive and negative drug controls were used to compare 196 self-controlled case series (SCCS), case-control (CC), and case-population (CP) design variants, using area under the receiver operating curve (AUC), mean square error (MSE) and coverage probability. Parameters that had major impacts on results were identified through logistic regression. RESULTS Using a specific ALI definition, AUCs ranged from 0.78 to 0.94, 0.64 to 0.92 and 0.48 to 0.85, for SCCS, CC and CP, respectively. MSE ranged from 0.12 to 0.40, 0.22 to 0.39 and 1.03 to 5.29, respectively. Variants adjusting for multiple drug use had higher coverage probabilities. Univariate regressions showed that high AUCs were achieved with SCCS using exposed time as the risk window. The top SCCS variant yielded an AUC = 0.93 and MSE = 0.22 and coverage = 86%, with 1/7 negative and 13/18 positive controls presenting significant estimates. CONCLUSIONS SCCS adjusting for multiple drugs and using exposed time as the risk window performed best in generating ALI-related drug safety alert and providing estimates of the magnitude of the risk. This approach may be useful for ad-hoc pharmacoepidemiology studies to support regulatory actions.
Collapse
Affiliation(s)
- Nicolas H Thurin
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Régis Lassalle
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Martijn Schuemie
- Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.,Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA
| | - Marine Pénichon
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Joshua J Gagne
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | | | - Jacques Benichou
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France.,INSERM U1181, Paris, France
| | - Alain Weill
- Caisse Nationale de l'Assurance Maladie, Paris, France
| | - Patrick Blin
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Nicholas Moore
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.,CHU de Bordeaux, Bordeaux, France
| | | |
Collapse
|
5
|
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 2020; 20:308. [PMID: 32546134 PMCID: PMC7298955 DOI: 10.1186/s12888-020-02711-z] [Citation(s) in RCA: 48] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 06/01/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants' classes. The objective of this study was to assess the putative association of each antidepressant and antidepressants' classes with movement disorders. METHODS Using VigiBase®, the WHO Pharmacovigilance database, disproportionality of movement disorders' reporting was assessed among adverse drug reactions related to any antidepressant, from January 1967 to February 2017, through a case/non-case design. The association between nine subtypes of movement disorders (akathisia, bruxism, dystonia, myoclonus, parkinsonism, restless legs syndrome, tardive dyskinesia, tics, tremor) and antidepressants was estimated through the calculation first of crude Reporting Odds Ratio (ROR), then adjusted ROR on four potential confounding factors: age, sex, drugs described as able to induce movement disorders, and drugs used to treat movement disorders. RESULTS Out of the 14,270,446 reports included in VigiBase®, 1,027,405 (7.2%) contained at least one antidepressant, among whom 29,253 (2.8%) reported movement disorders. The female/male sex ratio was 2.15 and the mean age 50.9 ± 18.0 years. We found a significant increased ROR for antidepressants in general for all subtypes of movement disorders, with the highest association with bruxism (ROR 10.37, 95% CI 9.62-11.17) and the lowest with tics (ROR 1.49, 95% CI 1.38-1.60). When comparing each of the classes of antidepressants with the others, a significant association was observed for all subtypes of movement disorders except restless legs syndrome with serotonin reuptake inhibitors (SRIs) only. Among antidepressants, mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan and fluvoxamine were associated with the highest level to movement disorders and citalopram, paroxetine, duloxetine and mirtazapine were the most frequently associated with movement disorders. An association was also found with eight other antidepressants. CONCLUSIONS A potential harmful association was found between movement disorders and use of the antidepressants mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan, fluvoxamine, citalopram, paroxetine, duloxetine, bupropion, clomipramine, escitalopram, fluoxetine, mianserin, sertraline, venlafaxine and vilazodone. Clinicians should beware of these adverse effects and monitor early warning signs carefully. However, this observational study must be interpreted as an exploratory analysis, and these results should be refined by future epidemiological studies.
Collapse
Affiliation(s)
- Alexis Revet
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France.
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France.
- Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, CHU de Toulouse, Hôpital Purpan, Place du Dr Baylac, TSA 40031, 31059, Toulouse cedex 9, France.
| | - François Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France
- CIC 1436, CHU de Toulouse, Toulouse, France
| | - Anne Roussin
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France
- CIC 1436, CHU de Toulouse, Toulouse, France
| | - Jean-Philippe Raynaud
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France
- Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, CHU de Toulouse, Hôpital Purpan, Place du Dr Baylac, TSA 40031, 31059, Toulouse cedex 9, France
| | - Maryse Lapeyre-Mestre
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France
- CIC 1436, CHU de Toulouse, Toulouse, France
| | - Thi Thu Ha Nguyen
- Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, Faculté de Médecine, Toulouse, France
- UMR 1027, Inserm, Université Toulouse III, Toulouse, France
| |
Collapse
|
6
|
Thurin NH, Lassalle R, Schuemie M, Pénichon M, Gagne JJ, Rassen JA, Benichou J, Weill A, Blin P, Moore N, Droz‐Perroteau C. Empirical assessment of case‐based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (
SNDS
). Pharmacoepidemiol Drug Saf 2020; 29:890-903. [DOI: 10.1002/pds.5038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 02/21/2020] [Accepted: 05/08/2020] [Indexed: 01/05/2023]
Affiliation(s)
- Nicolas H. Thurin
- Bordeaux PharmacoEpi, INSERM CIC1401Université de Bordeaux Bordeaux France
- INSERM U1219Université de Bordeaux Bordeaux France
| | - Régis Lassalle
- Bordeaux PharmacoEpi, INSERM CIC1401Université de Bordeaux Bordeaux France
| | - Martijn Schuemie
- Epidemiology AnalyticsJanssen Research and Development Titusville New Jersey USA
- Observational Health Data Sciences and Informatics (OHDSI) New York New York USA
| | - Marine Pénichon
- Bordeaux PharmacoEpi, INSERM CIC1401Université de Bordeaux Bordeaux France
| | - Joshua J. Gagne
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
| | | | - Jacques Benichou
- Department of Biostatistics and Clinical ResearchRouen University Hospital Rouen France
- INSERM U1181 Paris France
| | - Alain Weill
- Caisse Nationale de l'Assurance Maladie Paris France
| | - Patrick Blin
- Bordeaux PharmacoEpi, INSERM CIC1401Université de Bordeaux Bordeaux France
| | - Nicholas Moore
- Bordeaux PharmacoEpi, INSERM CIC1401Université de Bordeaux Bordeaux France
- INSERM U1219Université de Bordeaux Bordeaux France
- CHU de Bordeaux Bordeaux France
| | | |
Collapse
|
7
|
Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study. Mov Disord 2019; 35:176-180. [PMID: 31633228 DOI: 10.1002/mds.27876] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 08/22/2019] [Accepted: 09/04/2019] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Use of gabapentinoids is increasing. Following recent case reports, we investigated a putative risk of parkinsonism with pregabalin or gabapentin. METHODS A disproportionality analysis of 5,653,547 individual case safety reports in the World Health Organization individual case safety report database, VigiBase, compared all patients with parkinsonism who were receiving gabapentinoids with other patients. Results are shown as reporting odds ratios and the information component, an indicator of disproportionate Bayesian reporting. Sensitivity analyses included comparisons with drugs used for similar indications (amitriptyline, duloxetine) and exclusion of drugs that induce parkinsonism. RESULTS Among 5,653,547 reports, 4925 parkinsonism reports were found with pregabalin and 4881 with gabapentin. Gabapentin and pregabalin were associated with increased reporting odds ratio (2.16 [2.10-2.23], 2.43 [2.36-2.50]). Similar trends were found using information components after excluding drugs that induce parkinsonism and for pregabalin compared with amitriptyline or duloxetine. CONCLUSIONS This study found that gabapentinoids (particularly pregabalin) can be associated with parkinsonism. © 2019 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Tatiana Pacheco-Paez
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Universidad de La Sabana, Chía, Colombia
| | - François Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Leila Chebane
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France
| | - Maryse Lapeyre-Mestre
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| | - Christel Renoux
- Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Québec, Canada.,Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
| | - Jean-Louis Montastruc
- Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.,INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France
| |
Collapse
|
8
|
Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone: an observational postmarketing study. Eur J Clin Pharmacol 2019; 75:1593-1598. [DOI: 10.1007/s00228-019-02740-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 08/09/2019] [Indexed: 10/26/2022]
|
9
|
Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Bagheri H, Montastruc F, Montastruc J. Are lipid‐lowering drugs associated with a risk of cataract? A pharmacovigilance study. Fundam Clin Pharmacol 2019; 33:695-702. [DOI: 10.1111/fcp.12496] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Revised: 05/27/2019] [Accepted: 06/25/2019] [Indexed: 12/17/2022]
Affiliation(s)
- Fabien Despas
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Vanessa Rousseau
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Margaux Lafaurie
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Claire De Canecaude
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Geneviève Durrieu
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Haleh Bagheri
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - François Montastruc
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| | - Jean‐Louis Montastruc
- Faculty of Medicine, Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance, Pharmacoepidemiology and Drug Information, INSERM UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 CHU Toulouse University Hospital Toulouse France
| |
Collapse
|
10
|
Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie 2019; 74:279-288. [DOI: 10.1016/j.therap.2018.09.076] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Accepted: 09/29/2018] [Indexed: 01/28/2023]
|
11
|
Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes. Therapie 2019; 74:255-260. [DOI: 10.1016/j.therap.2018.09.074] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 09/17/2018] [Indexed: 11/21/2022]
|
12
|
Abou Taam M, Ferard C, Rocle P, Maison P. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity. Therapie 2019; 74:301-306. [DOI: 10.1016/j.therap.2019.01.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 11/02/2018] [Indexed: 12/14/2022]
|
13
|
Sommet A, Pariente A. Methods in pharmacoepidemiology. Therapie 2019; 74:187-197. [PMID: 30819408 DOI: 10.1016/j.therap.2018.11.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 11/26/2018] [Indexed: 01/04/2023]
Abstract
Pharmacoepidemiology is the study of interactions between drugs and human populations, investigating, in real conditions of life, benefits, risks and use of drugs. Pharmacoepidemiology applies to drugs and their pharmacological evaluations, the different methods also used in epidemiology to assess in real conditions of life, benefits, risks and use of drugs. Pharmacoepidemiologic studies are ad-hoc studies or studies on databases. Specific methods exist to measure drug exposure, as well as indicators of compliance and misuse of drugs. Various designs for descriptive and explanatory studies exist, in a context in which a growing proportion of studies are carried out using medico-administrative data. The limits traditionally affecting the study designs are modified in this context, almost any design selected for the conduct of a study from these databases then deriving from a cohort in whom the information has been recorded prospectively and exhaustively.
Collapse
Affiliation(s)
- Agnès Sommet
- Service de pharmacologie médicale et clinique, UMR Inserm 1027, CIC Inserm 1436, faculté de médecine, centre hospitalier universitaire, 31000 Toulouse, France.
| | - Antoine Pariente
- Inserm, Bordeaux population health research centre, team pharmacoepidemiology, UMR 1219, university of Bordeaux, 33076 Bordeaux, France; Pôle de santé publique, centre régional de pharmacovigilance de Bordeaux, service de pharmacologie médicale, CHU de Bordeaux, 33076 Bordeaux, France
| |
Collapse
|
14
|
Laroche ML, Sirois C, Reeve E, Gnjidic D, Morin L. Pharmacoepidemiology in older people: Purposes and future directions. Therapie 2019; 74:325-332. [PMID: 30773343 DOI: 10.1016/j.therap.2018.10.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 10/24/2018] [Indexed: 12/14/2022]
Abstract
Knowledge of the benefit/risk ratio of drugs in older adults is essential to optimise medication use. While randomised controlled trials are fundamental to the process of drug development and bringing new drugs to the market, they often exclude older adults, especially those suffering from frailty, multimorbidity and/or receiving polypharmacy. Therefore, it is generally unknown whether the benefits and harms of drugs established through pre-marketing clinical trials are translatable to the real-word population of older adults. Pharmacoepidemiology can provide real-world data on drug utilisation and drug effects in older people with multiple comorbidities and polypharmacy and can greatly contribute towards the goal of high quality use of drugs and well-being in older adults. A wide variety of pharmacoepidemiology studies can be used and exciting progress is being made with the use of novel and advanced statistical methods to improve the robustness of data. Coordinated and strategic initiatives are required internationally in order for this field to reach its full potential of optimising drug use in older adults so as to improve health care outcomes.
Collapse
Affiliation(s)
- Marie-Laure Laroche
- Centre de pharmacovigilance, de pharmacoépidemiologie et d'information sur les médicaments, CHU de Limoges, 97042 Limoges, France; Inserm 1248, faculté de médecine de Limoges, 87042 Limoges, France.
| | - Caroline Sirois
- Centre d'excellence sur le vieillissement de Québec, centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, G1S 4L8 Québec, Canada; Département de médecine sociale et préventive, université Laval, G1V 0A6 Québec, Canada
| | - Emily Reeve
- NHMRC-Cognitive Decline Partnership Centre, Kolling Institute of Medical Research, Northern Clinical School, Sydney Medical School, University of Sydney, NSW 2065 Saint-Leonard, Australia; Geriatric Medicine Research, Faculty of Medicine, Dalhousie University and Nova Scotia Health Authority, NS B3H 2Y9 Halifax, Canada; College of Pharmacy, Faculty of Health, Dalhousie University, B3H 4R2 Nova Scotia, Canada; College of Medicine, University of Saskatchewan, SK S7N 5C9 Saskatoon, Canada
| | - Danijela Gnjidic
- Sydney Pharmacy School and Charles Perkins Centre, University of Sydney, NSW 2006 Sydney, Australia
| | - Lucas Morin
- Aging Research Center, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| |
Collapse
|
15
|
Abstract
The evaluation of the real-life benefits and risks of statins in population is a major pharmacoepidemiological issue, given their widespread use for cardiovascular prevention. The purpose of this review was not to be exhaustive but to show the contributions of pharmacoepidemiology for various aspects of the evaluation of statins such as real-life drug use, effectiveness and risk. Statins are among the most used drugs in the world, but recent data show a slight decrease in use. Actual statin users are older, and have more comorbidities than those studied in clinical trials, but this does not seem to compromise their effectiveness, unlike the compliance issues that are common with these drugs. Beyond the known adverse reactions of statins from the clinical trials, risks of statins can be varied and sometimes difficult to evaluate, considering the ubiquity of cholesterol throughout the body, from drug or endogenous molecule metabolism to the construction of cell membranes or cell activities.
Collapse
Affiliation(s)
- Julien Bezin
- Inserm, UMR 1219, Bordeaux population health research center, team pharmacoepidemiology, université Bordeaux, 33076 Bordeaux, France.
| | - Nicholas Moore
- Inserm CIC1401, Inserm CR1219, Bordeaux PharmacoEpi, université et CHU de Bordeaux, 33076 Bordeaux, France
| |
Collapse
|
16
|
What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie 2018; 74:169-174. [PMID: 30389102 DOI: 10.1016/j.therap.2018.08.001] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 08/24/2018] [Indexed: 01/13/2023]
Abstract
Clinical evaluation of drugs before approval is based on the experimental design of clinical trial with randomization of drug exposure. Unfortunately, conclusions of clinical trials are necessarily limited to patients included into the trials. It is thus necessary to compare these experimental data coming from clinical trials with the real use of drugs in clinical practice. Pharmacoepidemiology is the study of interactions between drugs and human populations, investigating, in real conditions of life, benefits, risks and use of drugs. Pharmacoepidemiology applies to drugs the methods and/or reasoning of both pharmacology and epidemiology. The development of pharmacoepidemiology should improve the "rational drug use".
Collapse
|
17
|
Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase®. Fundam Clin Pharmacol 2018; 33:108-112. [DOI: 10.1111/fcp.12406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 08/01/2018] [Accepted: 08/07/2018] [Indexed: 01/06/2023]
Affiliation(s)
- François Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Justine Benevent
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Agnès Sommet
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| | - Jean-Louis Montastruc
- Service de Pharmacologie Médicale et Clinique; Centre de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament; INSERM U 1027, CIC 1436; Centre Hospitalier Universitaire - Faculté de Médecine; Université de Toulouse; 37 allées Jules Guesde 31000 Toulouse France
| |
Collapse
|
18
|
Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®. Eur J Clin Pharmacol 2018; 74:1673-1674. [PMID: 30094704 DOI: 10.1007/s00228-018-2536-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 08/03/2018] [Indexed: 11/26/2022]
Affiliation(s)
- François Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Justine Benevent
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - Leila Chebane
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Vanessa Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Geneviève Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Agnès Sommet
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Jean-Louis Montastruc
- Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
- INSERM UMR 1027, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
- CIC 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
| |
Collapse
|
19
|
Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase®. Drug Saf 2018; 41:1087-1096. [DOI: 10.1007/s40264-018-0693-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
20
|
Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. Tamoxifen and the risk of Parkinsonism: a case/non-case study. Eur J Clin Pharmacol 2018; 74:1181-1184. [DOI: 10.1007/s00228-018-2496-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 05/24/2018] [Indexed: 12/27/2022]
|